These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8532984)

  • 41. Trimipramine for refractory panic attacks.
    Cerra D
    Am J Psychiatry; 2006 Mar; 163(3):548. PubMed ID: 16513887
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparison of alprazolam and imipramine for treatment of outpatient depression.
    Overall JE; Biggs J; Jacobs M; Holden K
    J Clin Psychiatry; 1987 Jan; 48(1):15-9. PubMed ID: 3542981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder.
    Pollack MH; Otto MW; Tesar GE; Cohen LS; Meltzer-Brody S; Rosenbaum JF
    J Clin Psychopharmacol; 1993 Aug; 13(4):257-63. PubMed ID: 8376613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression.
    Rickels K; Chung HR; Csanalosi IB; Hurowitz AM; London J; Wiseman K; Kaplan M; Amsterdam JD
    Arch Gen Psychiatry; 1987 Oct; 44(10):862-6. PubMed ID: 3310952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder.
    Rizley R; Kahn RJ; McNair DM; Frankenthaler LM
    Psychopharmacol Bull; 1986; 22(1):167-72. PubMed ID: 2873609
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug treatment of panic disorder: early response to treatment as a predictor of final outcome.
    Albus M; Lecrubier Y; Maier W; Buller R; Rosenberg R; Hippius H
    Acta Psychiatr Scand; 1990 Nov; 82(5):359-65. PubMed ID: 2281806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study.
    Chouinard G; Annable L; Fontaine R; Solyom L
    Psychopharmacology (Berl); 1982; 77(3):229-33. PubMed ID: 6126907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychopharmacological treatment of panic disorder.
    Bowden CL
    Bull Menninger Clin; 1992; 56(2 Suppl A):A29-41. PubMed ID: 1623338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Xanax XR for panic disorder.
    Med Lett Drugs Ther; 2003 May; 45(1157):43-4. PubMed ID: 12766702
    [No Abstract]   [Full Text] [Related]  

  • 51. Commentary on 'The role of alprazolam for the treatment of panic disorder in Australia'.
    Lampe L
    Aust N Z J Psychiatry; 2012 Mar; 46(3):273-4. PubMed ID: 22391286
    [No Abstract]   [Full Text] [Related]  

  • 52. Pattern of placebo response in panic disorder.
    Shear MK; Leon AC; Pollack MH; Rosenbaum JF; Keller MB
    Psychopharmacol Bull; 1995; 31(2):273-8. PubMed ID: 7491379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 54. [The efficacy of alprazolam in the therapy of panic disorders].
    Diukova GM; Vorob'eva OV; Petrova EP; Smirnov SV; Tumalaeva ZN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(4):9-13. PubMed ID: 8533521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic dizziness presenting in a patient with panic disorder: response to imipramine.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2009 Mar; 67(1):121-2. PubMed ID: 19330229
    [No Abstract]   [Full Text] [Related]  

  • 56. A latent class approach to the external validation of respiratory and non-respiratory panic subtypes.
    Roberson-Nay R; Latendresse SJ; Kendler KS
    Psychol Med; 2012 Mar; 42(3):461-74. PubMed ID: 21846423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The structure of phobias in panic disorder.
    Argyle N; Solyom C; Solyom L
    Br J Psychiatry; 1991 Sep; 159():378-82. PubMed ID: 1958949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression.
    Leon AC; Shear MK; Klerman GL; Portera L; Rosenbaum JF; Goldenberg I
    J Clin Psychopharmacol; 1993 Oct; 13(5):327-31. PubMed ID: 8227491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
    Lydiard RB; Ballenger JC; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder.
    Hicks TV; Leitenberg H; Barlow DH; Gorman JM; Shear MK; Woods SW
    J Consult Clin Psychol; 2005 Jun; 73(3):506-14. PubMed ID: 15982148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.